EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prediction of Tacrolimus–Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models

Mengmeng Guan, Wanyi Zhou, Haoran Qin, Yi Xu, Di Zhao, Hui Xue, Nan Hu iD

Pharmaceutics · 22.05.2026 · 18 (6) · 639

DOI: 10.3390/pharmaceutics18060639 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.05.2026. Verfasst von Mengmeng Guan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changzhou Science and Technology Bureau, Jiangsu Pharmaceutical Association-Aosaikang Clinical Pharmacy Foundation, Changzhou Sci&Tech Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Posaconazole, a second-generation triazole antifungal used for the prevention or treatment of invasive fungal infections, has been shown to markedly increase tacrolimus exposure in vivo when co-administered, potentially leading to clinically significant adverse events. A physiologically based pharmacokinetic (PBPK) model was developed to predict tacrolimus–posaconazole interactions in renal transplant recipients with different CYP3A5 genotypes, to inform tacrolimus dose adjustment in clinical practice.

Methods

First, to obtain the critical inhibition parameters, in vitro enzyme kinetic studies were conducted. Based on these data, a whole-body physiologically based pharmacokinetic (PBPK) model for TAC was developed and validated in PK-Sim. A published, validated posaconazole PBPK model was applied concurrently. Model performance was evaluated against published pharmacokinetic data in healthy volunteers receiving tacrolimus with posaconazole. A virtual Chinese renal transplant recipient was generated by incorporating population-specific physiological parameters, including CYP3A5 genotype-dependent enzyme expression.

Results

In vitro experimental results demonstrated that POSA acts as a potent reversible competitive inhibitor of CYP3A4/5-mediated TAC metabolism. The tacrolimus PBPK model adequately captured pharmacokinetics across CYP3A5 genotypes, and tacrolimus pharmacokinetics during co-administration with posaconazole were also predicted. Compared with CYP3A5 expressers, nonexpressers showed greater variability in tacrolimus whole-blood concentrations and greater susceptibility to posaconazole-mediated interactions. The CYP3A5*3*3 genotype was associated with higher Cmax and AUC. Dose optimization simulations predicted that after 6–7 days of posaconazole co-administration, nonexpressers would require the reduction of tacrolimus dosing frequency from every 12 h to every 24 h to maintain trough concentrations within 8–15 ng/mL, whereas a 50% dose reduction was predicted to be optimal for expressers.

Conclusions

A tacrolimus–posaconazole PBPK drug–drug interaction model was developed for the population of renal transplant recipients and used to simulate tacrolimus trough concentrations across CYP3A5 genotypes and dosing regimens, supporting genotype-informed co-administration in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

CYP3A5drug–drug interactionsphysiologically based pharmacokineticposaconazoletacrolimus

Autor:innen und Institutionen

  • Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou 213000, China.
  • College of Pharmaceutical Sciences, Soochow University, Suzhou 215000, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China.
  • Department of Pharmacy, The First People's Hospital of Changzhou, Changzhou 213000, China.

ORCID-Profile: Nan Hu

Förderung

  • Changzhou Science and Technology Bureau
  • Jiangsu Pharmaceutical Association-Aosaikang Clinical Pharmacy Foundation
  • Changzhou Sci&Tech Program
  • Jiangsu Pharmaceutical Association–Aosaikang Clinical Pharmacy Foundation

Zitieren

APA

Guan, M., Zhou, W., Qin, H., Xu, Y., Zhao, D., Xue, H., & Hu, N. (2026). Prediction of Tacrolimus–Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models. Pharmaceutics, 18(6), 639. https://doi.org/10.3390/pharmaceutics18060639

Vancouver

Guan M, Zhou W, Qin H, Xu Y, Zhao D, Xue H, et al. Prediction of Tacrolimus–Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models. Pharmaceutics. 2026;18(6):639. doi:10.3390/pharmaceutics18060639

BibTeX
@article{Guan2026,
  author = {Guan, Mengmeng and Zhou, Wanyi and Qin, Haoran and Xu, Yi and Zhao, Di and Xue, Hui and Hu, Nan},
  title = {Prediction of Tacrolimus–Posaconazole Interactions in Renal Transplant Patients with Different CYP3A5 Genotypes, Based on Physiological Pharmacokinetic Models},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {639},
  doi = {10.3390/pharmaceutics18060639}
}
Kostenlos starten →